Will there be any new MAOIs?

Tyrima, brofaromine, pirlindole, toloxatone, and others drugs in development are new MAO inhibitors that pharmaceutical companies are hoping will have commercial potential. Given the current negative climate toward existing monoamine oxidase inhibitors, doctors will likely require that they work very well and are relatively free from side effects before they’ll prescribe them.